Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2026-02-28
Target enrollment:
Participant gender:
Summary
To evaluate the objective response rate (ORR) and disease control rate (DCR) of liposomal irinotecan monotherapy in the treatment of recurrent/refractory advanced gastric cancer.